FCGR3A and neoplasm: When combined with tumor-targeting antibodies, the Fc region of these therapeutic antibodies engages activating Fcγ receptors (e.g., FcγRIIIa) on neutrophils, triggering antibody dependent cell-mediated cytotoxicity (ADCC) and subsequently enhancing neutrophil-mediated tumor cell killing (3, 38).